John E. Tavis

Prof. John E. Tavis

1. Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, USA</br> 2. Institute of Drug and Biotherapeutic Innovation, Saint Louis University, Saint Louis, MO, USA
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SGShenghua Gao
Shenghua Gao
KSKatharina Sylvester
Katharina Sylvester
LSLetian Song
Letian Song
TCTobias Claff
Tobias Claff
LJLanlan Jing
Lanlan Jing
Peng ZhanPeng Zhan
Peng Zhan

1 July 2020 in Antiviral Research
Verified
Journal Article
Closed access
CRClaire Pierra Rouviere
Claire Pierra Rouviere
CDCyril B. Dousson
Cyril B. Dousson
John E. TavisJohn E. Tavis
John E. Tavis

1 May 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Georgia-Myrto PriftiGeorgia-Myrto Prifti
Georgia-Myrto Prifti
Dimitrios MoianosDimitrios Moianos
Dimitrios Moianos
Erofili GiannakopoulouErofili Giannakopoulou
Erofili Giannakopoulou
VPVasiliki Pardali
Vasiliki Pardali
John E. TavisJohn E. Tavis
John E. Tavis
Grigoris ZoidisGrigoris Zoidis
Grigoris Zoidis
Hepatitis B virus infection affects over 250 million chronic carriers, causing more than 800,000 deaths annually, although a safe and effective vaccine is available. Currently used antiviral agents, pegylated interferon and nucleos(t)ide analogues, have major drawbacks and fail to completely eradicate the virus from infected cells. Thus, achieving a “functional cure” of the infection remains a real challenge. Recent findings concerning the viral replication cycle have led to development of novel therapeutic approaches including viral entry inhibitors, epigenetic control of cccDNA, immune modulators, RNA interference techniques, ribonuclease H inhibitors, and capsid assembly modulators. Promising preclinical results have been obtained, and the leading molecules under development have entered clinical evaluation. This review summarizes the key steps of the HBV life cycle, examines the currently approved anti-HBV drugs, and analyzes novel HBV treatment regimens.

1 January 2018 in Antiviral Research
Verified
Journal Article
Closed access
KLKelly R. Long
Kelly R. Long
ELElena Lomonosova
Elena Lomonosova
QLQilan Li
Qilan Li
NPNathan L. Ponzar
Nathan L. Ponzar
JVJuan A. Villa
Juan A. Villa
John E. TavisJohn E. Tavis
John E. Tavis

7 December 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SGShenghua Gao
Shenghua Gao
LSLetian Song
Letian Song
TCTobias Claff
Tobias Claff
MWMolly Woodson
Molly Woodson
KSKatharina Sylvester
Katharina Sylvester
XLXinyong Liu
Xinyong Liu

1 April 2019 in Antiviral Research
Verified
Journal Article
Closed access
TETiffany C. Edwards
Tiffany C. Edwards
NMNagraj Mani
Nagraj Mani
BDBruce Dorsey
Bruce Dorsey
RKRamesh Kakarla
Ramesh Kakarla
RRRene Rijnbrand
Rene Rijnbrand
John E. TavisJohn E. Tavis
John E. Tavis